articleThe LancetApr 27, 2007Closed access

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

EKErnst-Rüdiger KusePCPloenchan ChetchotisakdCAClóvis Arns da CunhaMRMarkus RuhnkeCHCarlos H. Barrios

Khon Kaen University · Charité - Universitätsmedizin Berlin · +20 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

689
total citations
FWCI
39.84
Percentile
100%
References
23
Citations per year

Authors

21

Topics & keywords

Topics
Keywords
  • Micafungin
  • Medicine
  • Amphotericin B
  • Adverse effect
  • Discontinuation
  • Internal medicine
  • Surgery
  • Antifungal
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.